Related Experiment Videos
Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease
C Hoppe1, E Vichinsky, K Quirolo
1Department of Hematology/Oncology, Children's Hospital Oakland, California 94609, USA.
Insights
Hydroxyurea is safe and effective for young children with sickle cell disease. This pilot study showed improved hemoglobin levels and fewer hospitalizations without significant side effects, supporting its use in this population.
Area of Science:
- Pediatric Hematology
- Pharmacology
Background:
- Sickle cell disease (SCD) is a genetic blood disorder.
- Limited data exists on hydroxyurea treatment for young SCD patients.
Purpose of the Study:
- To evaluate the safety and efficacy of hydroxyurea in young children with SCD.
Main Methods:
- A pilot study followed eight children (mean age 3.7 years) on hydroxyurea therapy for approximately 137 weeks.
- Assessed hemoglobin levels, hospital admission rates, hospital days, toxicity, and growth/development.
Main Results:
- Hydroxyurea therapy increased total and fetal hemoglobin levels.
- Hospital admissions and days decreased significantly.
- No unexpected toxicity was observed, and growth/development remained unaffected.
Conclusions:
- Hydroxyurea appears to be a safe and effective treatment option for young children with sickle cell disease.
- Further research is warranted to confirm these findings in larger cohorts.
Abstract:
The efficacy and side effects of hydroxyurea in young children with sickle cell disease are unknown. The authors followed-up eight young children (mean age 3.7 years) during therapy with hydroxyurea for an average of 137 weeks. Total and fetal hemoglobin levels rose with hydroxyurea therapy. Hospital admission rates and total hospital days decreased during hydroxyurea therapy. No unexpected toxicity occurred, and growth and development were unaffected. This pilot study suggests that hydroxyurea is safe and effective in young children with sickle cell disease.